***Study now closed to recruitment***
m-BEP

Investigator initiated Phase 1b Study of Bcl-2 inhibition with venetoclax (ABT-199) and tamoxifen in metastatic oestrogen receptor (ER) positive breast cancer

Recruiting at: Royal Melbourne Hospital and Peter MacCallum Cancer Centre

Primary Investigator: Professor Geoff Lindeman

Clinical trial register: ACTRN12615000702516 

Women with ER positive metastatic breast cancer that is Bcl-2 positive and Her2 non-amplified may be eligible for inclusion in the m-BEP trial. Exposure to prior lines of endocrine therapy and chemotherapy is often acceptable, but cessation of anti-cancer therapy for 21 days prior to enrollment is essential.

Breast cancer clinical trial diagram